Table 2.
Description of ICGC-LIHC cohort
| Cluster | Group 1 (%) | Group 2 (%) | p-value (Chi-squared test) | Significance |
|---|---|---|---|---|
| Patients | 131 (47.12%) | 147 (52.88%) | ||
| Sex | ||||
| Male | 66 (50.38%) | 127 (86.39%) | 1.8273e-10 | *** |
| Female | 65 (49.62%) | 20 (13.61%) | ||
| Age | ||||
| Median (range) | 57 (18-81) | 61 (41.50%) | 0.8276 | |
| aged > 60 | 55 (41.98%) | 86 (58.50%) | ||
| AJCC stage | ||||
| I | 54 (41.22%) | 85 (57.82%) | 0.0082 | ** |
| II | 34 (25.95%) | 33 (22.45%) | 0.5881 | |
| III | 42 (32.06%) | 27 (18.37%) | 0.0124 | * |
| IV | 1 (0.76%) | 2 (1.36%) | 0.9200 | |
| Invasion | ||||
| Invasion | 41 (31.30%) | 36 (24.49%) | 0.2055 | |
| None | 90 (68.70%) | 111 (75.51%) | ||
| Mutations | ||||
| APOB | 12 (9.16%) | 22 (14.97%) | 0.1965 | |
| CSMD3 | 17 (12.98%) | 16 (10.88%) | 0.7243 | |
| MUC16 | 35 (26.72%) | 30 (20.41%) | 0.2719 | |
| MUC4 | 21 (16.03%) | 22 (14.97%) | 0.9371 | |
| PCLO | 13 (9.92%) | 25 (17.01%) | 0.1233 | |
| RYR2 | 19 (14.50%) | 18 (12.24%) | 0.7065 | |
| TP53 | 55 (41.98%) | 34 (23.13%) | 0.0012 | ** |
Abbreviations: *P < 0.05, **P < 0.01, ***P < 0.001.